Company Encyclopedia
View More
name
TIGERMED
03347.HK
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services.
697.22 B
03347.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking8/14
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.90%C
    • Profit Margin9.33%B
    • Gross Margin27.47%C
  • Growth ScoreD
    • Revenue YoY-4.51%D
    • Net Profit YoY-36.80%D
    • Total Assets YoY-6.24%D
    • Net Assets YoY-0.21%C
  • Cash ScoreC
    • Cash Flow Margin1071.86%B
    • OCF YoY-4.51%D
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreA
    • Gearing Ratio14.16%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | Tigermed continues to weaken, can the key support withstand the emotional backlash?

    Tigermed (3347.HK) has recently faced significant pressure, continuing to show weakness in early trading, with consecutive bearish candles indicating insufficient buying momentum in the market. The MACD indicator's death cross pattern persists, and the momentum histogram is diverging downward, with no signs of easing in the short-term downtrend. Over the past week, the stock price has fluctuated around HKD 48.00, with major funds showing an outflow trend, and there are few bargain-hunting buyers entering the market, leading to a cautious investor sentiment. The safety cushion is gradually being squeezed, and panic selling may emerge as support is tested; if it falls below HKD 47.00, panic selling in the market may intensify. From an industry perspective, the pharmaceutical services sector has recently shown significant divergence, lacking strong driving themes, leading to an overall increase in risk premium, with some funds choosing to retreat to safer investments. In the short term, if the HKD 48.00 area is lost again today, there is a risk that the stock price may fill the previous gap, exacerbating the bearish trend. If support holds successfully and trading volume improves, a brief structural rebound may occur, but the rebound's height will be limited by the downward moving average pressure, and speculative funds should enter and exit quickly. It is recommended to pay attention to MACD bullish divergence and volume reversal signals; if the trend shifts from a death cross to convergence, a light position trial may be considered. Overall, Tigermed currently has weak market confidence, and the emotional turning point has not yet been established, with a high risk of structural rebound failure. Investors should prioritize capital safety and position control, respond lightly to high volatility, and patiently wait for clear signs of strength before increasing positions

    Technical Forecast·
    Technical Forecast·
    Posts
    View More